acetylgalactosamine has been researched along with beta-Thalassemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crouch, PJ; Dames, S; Eisermann, M; Grigoriadis, G; Kysenius, K; Ng, GZ; Nualkaew, T; Schaeper, U; Vadolas, J; Vilcassim, S | 1 |
| Butler, JS; Fishman, S; Fitzgerald, K; Fleming, MD; Hettinger, JL; Liu, K; Racie, T; Schmidt, PJ; Visner, G | 1 |
2 other study(ies) available for acetylgalactosamine and beta-Thalassemia
| Article | Year |
|---|---|
SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.
Topics: Acetylgalactosamine; Animals; beta-Thalassemia; Deferiprone; Disease Models, Animal; Drug Therapy, Combination; Erythropoiesis; Female; Gene Expression Profiling; Hepcidins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnesium; Membrane Proteins; Mice; Mice, Inbred C57BL; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Serine Endopeptidases; Spleen; Zinc | 2021 |
RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of β-thalassemia intermedia.
Topics: Acetylgalactosamine; Anemia; Animals; beta-Thalassemia; Disease Models, Animal; Erythropoiesis; Hepcidins; Iron Overload; Liver; Membrane Proteins; Mice; RNA Interference; Serine Endopeptidases; Splenectomy | 2018 |